SLC6A8 and cancer: β-GPA is a high-affinity substrate for the creatine transporter, with an EC50 of ~ 13 μM.- considerably lower than that of creatine itself (EC50 of ~ 35 μM) [20] - and under investigation as competitive creatine transport blocker cancer drug [23].